Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma

Blood. 2021 Jun 17;137(24):3454-3459. doi: 10.1182/blood.2020009148.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antigens, CD19
  • Cell- and Tissue-Based Therapy
  • Histiocytes
  • Humans
  • Immunotherapy, Adoptive
  • Lymphoma, Large B-Cell, Diffuse* / therapy
  • Receptors, Chimeric Antigen* / genetics
  • T-Lymphocytes / immunology

Substances

  • Antigens, CD19
  • Receptors, Chimeric Antigen